This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Men's Health  • Prostate Disease  • Nutritional and Metabolic Disorders, Other  • Oncology  • Alert me on articles by topic

Shehzad Basaria, MD; Denis C. Muller, MS; Michael A. Carducci, MD; Josephine Egan, MD; Adrian S. Dobs, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Prostate cancer is one of the most common cancers in men. Androgen deprivation therapy (ADT) is frequently used in patients with recurrent or metastatic prostate cancer. Although ADT improves survival in a subset of patients, these men develop profound hypogonadism resulting in decreased lean body mass, decreased muscle strength, decreased quality of life, increased fat mass, sexual dysfunction, and osteoporosis.¹ Though less appreciated, these men also develop metabolic abnormalities. Within 3 months of initiation of ADT, these men develop significant hyperinsulinemia; however, there is no change in fasting glucose levels.² To the contrary, long-term ADT is not only associated with insulin resistance, but also with hyperglycemia and metabolic syndrome.^3-4 We have recently shown a significantly higher prevalence of insulin resistance, hyperglycemia, and metabolic syndrome in men with prostate cancer undergoing long-term ADT . . . [Full Text of this Article]

Methods


Results

Comment

AUTHOR INFORMATION

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Testosterone Making an Entry Into the Cardiometabolic World
Basaria and Dobs
Circulation 2007;116:2658-2661.
FULL TEXT